SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-21-011088
Filing Date
2021-05-12
Accepted
2021-05-12 09:00:32
Documents
52
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 475176
2 ex31-1.htm EX-31.1 11730
3 ex31-2.htm EX-31.2 11553
4 ex32-1.htm EX-32.1 4418
5 ex32-2.htm EX-32.2 4534
  Complete submission text file 0001493152-21-011088.txt   3279122

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE lixt-20210331.xml EX-101.INS 501431
7 XBRL SCHEMA FILE lixt-20210331.xsd EX-101.SCH 46094
8 XBRL CALCULATION FILE lixt-20210331_cal.xml EX-101.CAL 31869
9 XBRL DEFINITION FILE lixt-20210331_def.xml EX-101.DEF 185556
10 XBRL LABEL FILE lixt-20210331_lab.xml EX-101.LAB 315333
11 XBRL PRESENTATION FILE lixt-20210331_pre.xml EX-101.PRE 241157
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39717 | Film No.: 21913626
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences